Results 151 to 160 of about 70,715 (255)

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity. [PDF]

J Med Chem
Miao Y, Virtanen A, Zmajkovic J, Hilpert M, Skoda RC, Silvennoinen O, Haikarainen T.   +6 more
europepmc   +1 more source

Heparanase Level and Procoagulant Activity Are Increased in Thalassemia and Attenuated by Janus Kinase 2 Inhibition. [PDF]

Am J Pathol, 2020
Ghoti H, Ackerman S, Rivella S, Casu C, Nadir Y.   +4 more
europepmc   +1 more source

Reduced colony‐stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression

British Journal of Haematology, EarlyView.
Summary Targeting the colony‐stimulating factor 1 receptor (CSF1R) to remove tumour‐associated macrophages is being explored as cancer therapy. This strategy may be relevant for chronic lymphocytic leukaemia (CLL), which strongly depends on support from myeloid cells.
Natascha Rosen, Guillermo Rodriguez‐Real, Alexander F. vom Stein, Luca D. Schreurs, Trong‐Hieu Nguyen, Viktoria Kohlhas, Thanh‐Tung Truong, Maximilian Koch, Sebastian Reinartz, Sumiya Iqbal, Shaista Ilyas, Sanjay Mathur, Nina Reinart, Phuong‐Hien Nguyen, Michael Hallek   +14 more
wiley   +1 more source

The methyl-CpG binding domain 2 regulates peptidylarginine deiminase 4 expression and promotes neutrophil extracellular trap formation via the Janus kinase 2 signaling pathway in experimental severe asthma. [PDF]

Ann Med
Peng B, Yan MY, Chen YR, Sun F, Xiang XD, Liu D.   +5 more
europepmc   +1 more source

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

British Journal of Haematology, EarlyView.
Summary Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.
Juan‐Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo, Manuel Pérez‐Encinas, José‐María Raya, María‐Teresa Gómez‐Casares, Francisca Ferrer‐Marín, Alberto Hernández‐Sánchez, María‐Laura Fox, Anna Angona, Beatriz Cuevas, María‐Isabel Mata‐Vázquez, Rosa Ayala, Natalia de las Heras, Elvira Mora, Valentín García‐Gutiérrez, Alicia Senín, Jasson Villarreal, Blanca Xicoy, Raúl Pérez‐López, María García‐Fortes, Sonia González de Villambrosia, Elena Magro, María‐José Ramírez, Paula Gómez, Angel Ramírez‐Payer, Clara Martínez‐Valverde, Lucía Pérez‐Lamas, Carmen García‐Hernández, Mercedes Gasior, Luis‐Miguel Juárez‐Salcedo, Francisco Ibáñez, María‐Luisa Antelo, Lucía Guerrero, Alberto Alvarez‐Larrán, Arturo Pereira, on behalf of the Spanish MPN Group (GEMFIN)   +35 more
wiley   +1 more source

Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy. [PDF]

Inflamm Res
Chen P, Long J, Zhang J, Xie F, Wu W, Tian Z, Zhang S, Yu K.   +7 more
europepmc   +1 more source

In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2. [PDF]

Viruses, 2020
Wang J, Prinz RA, Liu X, Xu X.
europepmc   +1 more source

Pericardial Adipose Tissue-Derived Leptin Promotes Myocardial Apoptosis in High-Fat Diet-Induced Obese Rats Through Janus Kinase 2/Reactive Oxygen Species/Na+/K+-ATPase Signaling Pathway. [PDF]

J Am Heart Assoc, 2021
Wang P, Luo C, Zhu D, Song Y, Cao L, Luan H, Gao L, Zheng S, Li H, Tian G.   +9 more
europepmc   +1 more source

CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib

British Journal of Haematology, EarlyView.
Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq, Deepak Iyer, Patrick Wang, Mariusz Shrestha, Cuihong Wei, Aaron D. Schimmer, Hong Chang   +6 more
wiley   +1 more source